Regulation of Histone H3 Lysine 9 Methylation in Inflammation
Xiaomin Ren,Rong Wang,Xuan Yu,Bo Cai,Fei Guo
DOI: https://doi.org/10.1080/26895293.2021.1931477
IF: 1.044
2021-01-01
All Life
Abstract:Inflammation is a defense mechanism that the immune system uses in response to harmful stimuli such as pathogens, damaged cells, toxic compounds, or irradiation. These stimuli may induce inflammatory response and potentially tissue damage in respiratory, cardiovascular, digestive, nervous, endocrine, urinary, or reproductive systems. Inflammatory diseases include a broad array of disorders and conditions that are characterized by inflammation, ranging from autoimmune disease, atopic dermatitis, asthma, chronic obstructive pulmonary disease, inflammatory bowel disease, glomerulonephritis, hepatitis, reperfusion injury, transplant rejection, diabetes, cancer, Parkinson’s disease, multiple sclerosis, to depression. Epigenetic mechanisms play crucial roles in many biological processes by regulating transcriptional activation or repression. Histone post-translational modifications have emerged as prospective therapeutic targets. Methylation of histone 3 at lysine 9 is one of the most highly conserved epigenetic marks that correlate well with gene silencing. The methylation status of H3K9 modulates immune cell differentiation and immune responses and therefore influences the outcome of cancer, infection, and other inflammatory diseases. Here, we review the high impact and innovate discoveries in this field, highlight the critical role of the H3K9 methylation/de-methylation in human inflammatory diseases, discuss potential new therapeutic strategies based on a better understanding of the biology of H3K9 methylation modifications.Abbreviations: 2OG: 2-oxoglutarate; AOL: Amine oxidase-like; ChIP: Chromatin immunoprecipitation; CNS2: conserved noncoding sequence 2; COPD: Chronic obstructive pulmonary disease; CoREST: Corepressor of RE1 silencing transcription factor; CPP: Cell-permeant protein; CTLA4: Cytotoxic T-lymphocyte antigen 4; DCs: Dendritic cells; DN: Diabetic nephropathy; ESRD: End-stage renal disease; ETDB: SET domain bifurcated histone lysine methyltransferase; FAD: Flavin adenine dinucleotide; FEV1%: The percentage of forced expiratory volume in one second; FEV1/FVC: Forced expiratory volume in one second (FEV1)/Forced vital capacity (FVC) value; FOXP3: forkhead/winged helix transcription factor 3; GLP: G9a like protein; GZMB: Granzyme B; H3K27me3: Trimethylation of lysine 27 on histone H3; H3K4me3: Trimethylation of lysine 4 on histone H3; H3K9: Histone 3 Lysine 9; HG: Hyperglycemia; HDAC3: Histone deacetylase 3; HP1: Heterochromatin protein 1; I/R: Ischemia/Reperfusion; IBD: Inflammatory bowel disease; IFN-: Interferon-; IFNG: Interferon Gamma; IL-2: Interleukin-2; ILC2s: Group 2 innate lymphoid cells; JMJD: Jumonji domain-containing protein; iTreg: inducible Treg; KDM: Lysine-specific demethylase; LPS: Lipopolysaccharide; LSD: Lys-specific demethylase; MCP-1: Monocyte chemoattractant protein-1; MCSF: Macrophage colony-stimulating factor; MIP-1: Macrophage inflammatory protein-1; MS: Metabolic syndrome; NAFLD: Non-alcoholic fatty liver disease; NKRF: NF-kappaB repressing factor; NOR: Norisoboldine; NuRD: Nucleosome remodeling and deacetylase; OxLDL: Oxidized low-density lipoprotein; PBMCs: Peripheral blood monocytes; PHD: Plant homology domain; Poly I:C: Polyinosinic:polycytidylic acid; PPARγ: Peroxisome proliferator-activated receptor gamma; PTMs: Post-translational modifications; SUV3-9: Suppressor of variegation3-9; T1D: Type 1 diabetes; TLRs: Toll like receptors; TSDR: TGF-β sensitive region and Treg cell specific demethylated region; Treg: Regulatory T cell; VSMCs: Vascular smooth muscle cells.